Further, a recent clinical study that examined the sleep architecture and CSF biomarkers (tau and amyloid-β42) in patients with AD (which progressed from having subjective cognitive impairment to mild cognitive impairment to AD), found that both REM and NREM sleep were disturbed. The gene discussed is MAPT; the disease is Alzheimer disease.